MedDataX Logo

Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-Dopa

NCT ID: NCT00613301

Last Updated: 2014-06-06

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

416 participants

Study Classification

OBSERVATIONAL

Study Start Date

2004-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The survey is conducted to collect safety and effectiveness information in Parkinson's Disease patients treated with Pramipexole without concomitant L-Dopa supplementation in the daily clinical settings in Japan.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole

NCT00615914

Parkinson Disease
COMPLETED

Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients

NCT02177357

Parkinson Disease
COMPLETED PHASE3

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

NCT00560508

Parkinson Disease
COMPLETED PHASE2/PHASE3

Special Survey on PD Patients With Renal Dysfunction

NCT00613756

Parkinson Disease
COMPLETED

Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's Disease

NCT00539214

Parkinson Disease
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with Parkinson's disease who do not receive L-Dopa supplementation

Exclusion Criteria

Patients should have been treated according to the Japanese insert slip
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Boehringer Ingelheim

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boehringer Ingelheim Investigational Site 11

Akita, , Japan

Site Status

Boehringer Ingelheim Investigational Site 95

Anan, , Japan

Site Status

Boehringer Ingelheim Investigational Site 1

Asahikawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site 2

Asahikawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site 26

Chiba, , Japan

Site Status

Boehringer Ingelheim Investigational Site 27

Chiba, , Japan

Site Status

Boehringer Ingelheim Investigational Site 60

Fuji, , Japan

Site Status

Boehringer Ingelheim Investigational Site 49

Fujisawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site 25

Fukaya, , Japan

Site Status

Boehringer Ingelheim Investigational Site 103

Fukuoka, , Japan

Site Status

Boehringer Ingelheim Investigational Site 104

Fukuoka, , Japan

Site Status

Boehringer Ingelheim Investigational Site 105

Fukuoka, , Japan

Site Status

Boehringer Ingelheim Investigational Site 106

Fukuoka, , Japan

Site Status

Boehringer Ingelheim Investigational Site 56

Gifu, , Japan

Site Status

Boehringer Ingelheim Investigational Site 80

Habikino, , Japan

Site Status

Boehringer Ingelheim Investigational Site 3

Hakodate, , Japan

Site Status

Boehringer Ingelheim Investigational Site 59

Hamamatsu, , Japan

Site Status

Boehringer Ingelheim Investigational Site 64

Handa, , Japan

Site Status

Boehringer Ingelheim Investigational Site 82

Himeji, , Japan

Site Status

Boehringer Ingelheim Investigational Site 76

Hirakata, , Japan

Site Status

Boehringer Ingelheim Investigational Site 86

Hiroshima, , Japan

Site Status

Boehringer Ingelheim Investigational Site 87

Hiroshima, , Japan

Site Status

Boehringer Ingelheim Investigational Site 8

Ichinoseki, , Japan

Site Status

Boehringer Ingelheim Investigational Site 118

Kagoshima, , Japan

Site Status

Boehringer Ingelheim Investigational Site 15

Kamisu, , Japan

Site Status

Boehringer Ingelheim Investigational Site 50

Kashiwazaki, , Japan

Site Status

Boehringer Ingelheim Investigational Site 107

Kasuga, , Japan

Site Status

Boehringer Ingelheim Investigational Site 24

Kawagoe, , Japan

Site Status

Boehringer Ingelheim Investigational Site 46

Kawasaki, , Japan

Site Status

Boehringer Ingelheim Investigational Site 111

Kawatana, , Japan

Site Status

Boehringer Ingelheim Investigational Site 112

Kawatana, , Japan

Site Status

Boehringer Ingelheim Investigational Site 99

Kitakyushu, , Japan

Site Status

Boehringer Ingelheim Investigational Site 117

Kiyotake, , Japan

Site Status

Boehringer Ingelheim Investigational Site 83

Kobe, , Japan

Site Status

Boehringer Ingelheim Investigational Site 67

Koga, , Japan

Site Status

Boehringer Ingelheim Investigational Site 21

Koshiagya, , Japan

Site Status

Boehringer Ingelheim Investigational Site 63

Kōnan, , Japan

Site Status

Boehringer Ingelheim Investigational Site 12

Kōriyama, , Japan

Site Status

Boehringer Ingelheim Investigational Site 13

Kōriyama, , Japan

Site Status

Boehringer Ingelheim Investigational Site 100

Kurume, , Japan

Site Status

Boehringer Ingelheim Investigational Site 68

Kyoto, , Japan

Site Status

Boehringer Ingelheim Investigational Site 69

Kyoto, , Japan

Site Status

Boehringer Ingelheim Investigational Site 70

Kyoto, , Japan

Site Status

Boehringer Ingelheim Investigational Site 71

Kyoto, , Japan

Site Status

Boehringer Ingelheim Investigational Site 19

Maebashi, , Japan

Site Status

Boehringer Ingelheim Investigational Site 20

Maebashi, , Japan

Site Status

Boehringer Ingelheim Investigational Site 55

Matsumoto, , Japan

Site Status

Boehringer Ingelheim Investigational Site 88

Mihara, , Japan

Site Status

Boehringer Ingelheim Investigational Site 54

Minobu, , Japan

Site Status

Boehringer Ingelheim Investigational Site 116

Miyakonojō, , Japan

Site Status

Boehringer Ingelheim Investigational Site 114

Miyazaki, , Japan

Site Status

Boehringer Ingelheim Investigational Site 115

Miyazaki, , Japan

Site Status

Boehringer Ingelheim Investigational Site 77

Moriguchi, , Japan

Site Status

Boehringer Ingelheim Investigational Site 9

Morioka, , Japan

Site Status

Boehringer Ingelheim Investigational Site 23

Morohongō, , Japan

Site Status

Boehringer Ingelheim Investigational Site 53

Mukai-awagasaki, , Japan

Site Status

Boehringer Ingelheim Investigational Site 4

Muroran, , Japan

Site Status

Boehringer Ingelheim Investigational Site 51

Nagaoka, , Japan

Site Status

Boehringer Ingelheim Investigational Site 61

Nagoya, , Japan

Site Status

Boehringer Ingelheim Investigational Site 62

Nagoya, , Japan

Site Status

Boehringer Ingelheim Investigational Site 97

Nangōku, , Japan

Site Status

Boehringer Ingelheim Investigational Site 102

Naoetsu, , Japan

Site Status

Boehringer Ingelheim Investigational Site 28

Narita, , Japan

Site Status

Boehringer Ingelheim Investigational Site 93

Narutō, , Japan

Site Status

Boehringer Ingelheim Investigational Site 17

Nikkō, , Japan

Site Status

Boehringer Ingelheim Investigational Site 119

Nishihara, , Japan

Site Status

Boehringer Ingelheim Investigational Site 81

Nishinomiya, , Japan

Site Status

Boehringer Ingelheim Investigational Site 72

Osaka, , Japan

Site Status

Boehringer Ingelheim Investigational Site 98

Ōkawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site 66

Ōtsu, , Japan

Site Status

Boehringer Ingelheim Investigational Site 108

Saga, , Japan

Site Status

Boehringer Ingelheim Investigational Site 45

Sagamihara, , Japan

Site Status

Boehringer Ingelheim Investigational Site 22

Saitama, , Japan

Site Status

Boehringer Ingelheim Investigational Site 79

Sakai, , Japan

Site Status

Boehringer Ingelheim Investigational Site 52

Sanjō, , Japan

Site Status

Boehringer Ingelheim Investigational Site 90

Sanyōonoda, , Japan

Site Status

Boehringer Ingelheim Investigational Site 5

Sapporo, , Japan

Site Status

Boehringer Ingelheim Investigational Site 6

Sapporo, , Japan

Site Status

Boehringer Ingelheim Investigational Site 7

Sapporo, , Japan

Site Status

Boehringer Ingelheim Investigational Site 110

Sasebo, , Japan

Site Status

Boehringer Ingelheim Investigational Site 78

Sayama, , Japan

Site Status

Boehringer Ingelheim Investigational Site 10

Sendai, , Japan

Site Status

Boehringer Ingelheim Investigational Site 91

Shimonoseki, , Japan

Site Status

Boehringer Ingelheim Investigational Site 18

Shimotsuke, , Japan

Site Status

Boehringer Ingelheim Investigational Site 85

Shingū, , Japan

Site Status

Boehringer Ingelheim Investigational Site 57

Shizuoka, , Japan

Site Status

Boehringer Ingelheim Investigational Site 58

Shizuoka, , Japan

Site Status

Boehringer Ingelheim Investigational Site 73

Suita, , Japan

Site Status

Boehringer Ingelheim Investigational Site 101

Tagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site 96

Takamatsu, , Japan

Site Status

Boehringer Ingelheim Investigational Site 74

Takatsuki, , Japan

Site Status

Boehringer Ingelheim Investigational Site 75

Takatsuki, , Japan

Site Status

Boehringer Ingelheim Investigational Site 109

Togitsu, , Japan

Site Status

Boehringer Ingelheim Investigational Site 92

Tokushima, , Japan

Site Status

Boehringer Ingelheim Investigational Site 30

Tokyo Adachi-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site 31

Tokyo Arakawa-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site 40

Tokyo Bunkyo-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site 41

Tokyo Bunkyo-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site 42

Tokyo Bunkyo-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site 38

Tokyo Chiyoda-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site 32

Tokyo Itabashi-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site 33

Tokyo Itabashi-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site 43

Tokyo Meguro-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site 39

Tokyo Nakano-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site 34

Tokyo Ota-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site 35

Tokyo Ota-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site 36

Tokyo Shinjuku-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site 37

Tokyo Shinjuku-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site 44

Tokyo Toshima-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site 113

Tomiai, , Japan

Site Status

Boehringer Ingelheim Investigational Site 14

Toride, , Japan

Site Status

Boehringer Ingelheim Investigational Site 65

Tsu, , Japan

Site Status

Boehringer Ingelheim Investigational Site 16

Tsukuba, , Japan

Site Status

Boehringer Ingelheim Investigational Site 29

Urayasu, , Japan

Site Status

Boehringer Ingelheim Investigational Site 84

Wakayama, , Japan

Site Status

Boehringer Ingelheim Investigational Site 89

Yamaguchi, , Japan

Site Status

Boehringer Ingelheim Investigational Site 47

Yokohama, , Japan

Site Status

Boehringer Ingelheim Investigational Site 48

Yokohama, , Japan

Site Status

Boehringer Ingelheim Investigational Site 94

Yoshinogawa, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

248.549

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients
NCT01361009 COMPLETED
Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease
NCT00240409 COMPLETED PHASE3
The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease
NCT01470859 COMPLETED NA
Pivotal Study in Advanced Parkinsons Disease Patients
NCT00466167 COMPLETED PHASE3
Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole
NCT02236728 COMPLETED
A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.
NCT00903838 TERMINATED PHASE2
Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
NCT00601523 COMPLETED PHASE3
Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients
NCT00479401 COMPLETED PHASE3
Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease
NCT02172573 COMPLETED PHASE3
A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients
NCT00402233 COMPLETED PHASE4
Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
NCT00297778 COMPLETED PHASE4
Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment
NCT00651183 COMPLETED
Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease
NCT02906488 COMPLETED
Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical Practice
NCT01061567 COMPLETED
Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease
NCT00666653 COMPLETED PHASE1
Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease
NCT02233023 COMPLETED PHASE4
Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients
NCT01191944 COMPLETED PHASE3
Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease
NCT01673724 COMPLETED PHASE4
A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)
NCT01294800 COMPLETED PHASE2
A Study to Evaluate in Patients With Parkinsonian Type Disorders
NCT03683225 ACTIVE_NOT_RECRUITING PHASE2
A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.
NCT03845387 COMPLETED PHASE2
The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa
NCT03521635 COMPLETED PHASE4
A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease
NCT01494532 COMPLETED PHASE4
Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease Patients
NCT02073981 COMPLETED
Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease
NCT00558025 COMPLETED PHASE3